ArticleEndocrine, metabolic & immune disorders drug targets2026
From Limited Samples to Mechanistic Insights: Exploratory Identification and Functional Validation of a hsa_circ_0062400/hsa_circ_0002397-miR-338-3p-NRP1 Axis in Myasthenia Gravis
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCircRNAs are implicated in various autoimmune diseases, such as Myasthenia Gravis (MG), yet their regulatory mechanisms remain poorly understood. This research investigated the regulatory network of circRNAs, miRNAs, and mRNAs in modulating MG progression. MATERIALS AND
methodsThree MG patients (male: female = 1:2) and three healthy controls were enrolled for microarray analysis. The “Limma” package was employed to identify the differentially expressed circRNAs (DECs). Target miRNAs of DECs were predicted via the CircInteractome database, while target genes of miRNAs were predicted utilizing miRWalk, miRTarbase, and TargetScan databases. Cytoscape software was applied to establish the circRNAs-miRNAs-mRNAs network. Thereafter, a dual-luciferase reporter assay was conducted to validate the targeted regulatory relationship between hsa_circ_0062400, hsa_circ_0002397, and miR-338-3p. The expression of NRP1 was measured by qRT-PCR and Western blotting, and the cell viability of Jurkat cells was evaluated via CCK-8 assay. The levels of cytokines (IL-2, IL-6, IFN-γ, TNF-α) after NRP1 knockout were detected by ELISA.
results4 circRNAs, 2 miRNAs, and 11 target genes associated with MG pathogenesis were identified to construct a ceRNA regulatory network. In-vitro assays validated the targeted interactions between hsa_circ_0062400, hsa_circ_0002397, and miR-338-3p. miR-338-3p negatively regulated both protein and mRNA levels of NRP1. Further, silencing hsa_circ_0062400 or hsa_circ_ 0002397 markedly suppressed NRP1 expression and Jurkat cell proliferation, which was reversed by miR-338-3p inhibitor. Moreover, NRP1 affected the levels of cytokines in Jurkat cells. DISCUSSION: The circRNAs were demonstrated to be closely associated with MG etiology, which was also supported by our current discovery that hsa_circ_0062400 and hsa_circ_0002397 regulated the level of NRP1 by sponging miR-338-3p in MG. However, the roles of hsa_circ_0062400 and hsa_circ_0002397 in MG have been rarely reported, which requires further validation. Limitations of this study included a small, gender-imbalanced sample size for microarray analysis and incomplete verification of the ceRNA network. In addition, functional experiments were limited to Jurkat cells, and more in-vivo validation assays were lacking.
conclusionCollectively, the present study revealed MG pathogenesis and also provided potential treatment targets for the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.